Cann Global Limited (ASX: CGB) has introduced the launch in Australia of the corporate’s distinctive formulation of medical Cannabis tablets by way of its joint-venture partnership with Canntab Therapeutics Limited.

Cann Global entered into a 50/50 Joint Venture with Canntab Therapeutics in January 2018 to carry their suite of laborious tablet cannabinoid formulations to Australia.

Canntab Therapeutics manufactures and distributes a collection of laborious tablet cannabinoid formulations in a number of doses and timed-release combos. Canntab Therapeutics is already the main innovator in cannabinoid and terpene blends in laborious tablet kind for therapeutic functions in Canada.

Cann Global is happy to verify the import allow has been acquired and an preliminary order for these merchandise has been made so as to launch the merchandise into the Australian marketplace for the primary time.

Cann Global is importing six merchandise out of the Canntab vary for distribution to the Australian market. The vary CGB is importing accommodates two THC merchandise, two CBD solely and two THC/CBD blends. The CBD merchandise might additionally profit from the TGA’s proposed modification to create a brand new Schedule three entry for cannabidiol (CBD) which can permit better entry to CBD merchandise.

Cann Global has additionally revealed it has entered into a Grant Agreement with Applied Cannabis Research (ACR) to present a grant to ACR to assist the Cannabinoid Medicine Observational Study (CMOS) on the laborious tablet cannabinoid formulations produced by Canntab. This is the biggest observational research ever undertaken in Australia for Cannabinoid Medicine merchandise. CMOS will accumulate information from 20,000 sufferers nationwide to assess the protection and efficacy of medicinal hashish merchandise.

Cann Global will provide these merchandise via its three way partnership with Canntab to the CMOS Study with the purpose to accumulate information about health-related outcomes from sufferers prescribed with these merchandise.

Unlike medical trials, an observational research solely requires a really small funding and the corporate will obtain income when a affected person collaborating within the research purchases the CannTab product as prescribed by a Medical Practitioner.

Participation on this CMOS will present early publicity of the product in Australia to each medical practitioners and sufferers. CMOS supplies a first-of-its-kind alternative to seize information from a broader vary of Australian prescribers and sufferers than in current research.

 

Source link